Think Investments’s Arbutus Biopharma ABUS Stock Holding History

Think Investments’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-2,000,000	Closed	-$7.1M	–	26
2020 Q4	$7.1M	Hold	2,000,000	–	–	1.08%	22
2020 Q3	$6.26M	Buy	+2,000,000	New	+$6.08M	1.15%	20

Other funds holding ABUS

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Think Investments's ABUS Position: Q1 2021 in Review

Think Investments sold out of Arbutus Biopharma (ABUS) in Q1 2021, closing a stake of 2,000,000 shares — an estimated $7.1M sold.

Think Investments first reported a position in ABUS in Q3 2020 and held it in 2 quarters. The position peaked at $7.1M in Q4 2020. 94 funds tracked by Wall St. Rank hold ABUS as of Q1 2021.

Think Investments reported no remaining Arbutus Biopharma position as of Q1 2021 after selling out during the quarter.
Think Investments sold 2,000,000 Arbutus Biopharma shares in Q1 2021, an estimated $7.1M.
Think Investments first reported a position in Arbutus Biopharma in Q3 2020 and held it in 2 quarters.
Think Investments's Arbutus Biopharma position peaked at $7.1M in Q4 2020.
94 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2021.

Based on Think Investments's 13F filing for Q1 2021, filed 17 May 2021.